KR20090108230A - 비만 억제 또는 치료용 조성물 - Google Patents
비만 억제 또는 치료용 조성물 Download PDFInfo
- Publication number
- KR20090108230A KR20090108230A KR1020080033538A KR20080033538A KR20090108230A KR 20090108230 A KR20090108230 A KR 20090108230A KR 1020080033538 A KR1020080033538 A KR 1020080033538A KR 20080033538 A KR20080033538 A KR 20080033538A KR 20090108230 A KR20090108230 A KR 20090108230A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- present
- obesity
- red ginseng
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 208000008589 Obesity Diseases 0.000 title claims abstract description 49
- 235000020824 obesity Nutrition 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 97
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 53
- 241001480003 Chaetothyriales Species 0.000 claims abstract description 25
- 238000000855 fermentation Methods 0.000 claims abstract description 21
- 230000004151 fermentation Effects 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 9
- 230000009467 reduction Effects 0.000 abstract description 29
- 108010092277 Leptin Proteins 0.000 abstract description 20
- 108010076365 Adiponectin Proteins 0.000 abstract description 19
- 102000011690 Adiponectin Human genes 0.000 abstract description 19
- 102000016267 Leptin Human genes 0.000 abstract description 19
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract description 19
- 229940039781 leptin Drugs 0.000 abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000004580 weight loss Effects 0.000 abstract description 7
- 244000274050 Platycodon grandiflorum Species 0.000 abstract description 4
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 3
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 240000004371 Panax ginseng Species 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 235000008434 ginseng Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000005228 liver tissue Anatomy 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 7
- 229960003105 metformin Drugs 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 102000005861 leptin receptors Human genes 0.000 description 3
- 108010019813 leptin receptors Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000168720 Panax japonicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000218646 Cedrus deodara Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000036391 Genetic obesity Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100030874 Leptin Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241001527087 Panax vietnamensis Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000037493 inherited obesity Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 235000021142 long-term diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
시료명 | 함량(중량비) |
조성물 A 투여군 | 흑효모발효 추출물:길경 추출물= 1:1 |
조성물 B 투여군 | 흑효모발효 추출물:길경 추출물:홍삼추출물= 1:1:1 |
조성물 C 투여군 | 흑효모발효 추출물:길경 추출물:홍삼추출물= 1:1:2 |
조성물 D 투여군 | 흑효모발효 추출물:길경 추출물:홍삼추출물= 1:1:4 |
시료명 | 초기 | 1일 | 7일 | 14일 | 21일 |
정상군 | 22.09 ± 1.06 | 24.03 ± 1.39 | 24.33 ± 1.05 | 26.07 ± 1.03 | 27.97 ± 0.98 |
음성 대조군 | 40.26 ± 1.10 | 42.66 ± 0.82 | 44.01 ± 1.07 | 45.93 ± 1.01 | 48.41 ± 1.38 |
홍삼추출물 투여군 | 40.14 ± 1.04 | 42.39 ± 1.12 | 44.30 ± 1.29 | 46.29 ± 0.89 | 47.91 ± 1.25 |
조성물 A 투여군 | 40.30 ± 0.99 | 42.10 ± 1.00 | 44.11 ± 1.34 | 46.01 ± 1.52 | 46.53 ± 1.74 |
조성물 B 투여군 | 40.51 ± 1.60 | 42.39 ± 1.46 | 44.39 ± 1.61 | 46.11 ± 1.68 | 46.49 ± 1.67 |
조성물 C 투여군 | 40.29 ± 1.22 | 42.44 ± 1.20 | 43.91 ± 0.98 | 45.06 ± 1.28 | 45.73 ± 1.26 |
조성물 D 투여군 | 40.36 ± 1.51 | 42.41 ± 1.49 | 44.06 ± 0.95 | 45.26 ± 1.11 | 45.29 ± 1.36 |
메트포르민 250 mg/kg (양성 대조군) | 40.19 ± 1.04 | 6.00 ± 1.09 | 43.80 ± 1.13 | 45.23 ± 1.23 | 45.60 ± 1.36 |
시료명 | 27일 | 희생 시 | 정상군 대비 최종 체중변화율(%) |
정상군 | 30.44 ± 1.05 | 27.56 ± 1.19 | - |
음성 대조군 | 51.41± 1.54 | 49.23 ± 1.77 | 63.97 % 증가 |
홍삼추출물 투여군 | 48.60 ± 1.31 | 46.14 ± 1.34 | 33.1 % 감소 |
조성물 A 투여군 | 47.04 ± 1.82 | 45.21 ± 1.49 | 45.2 % 감소 |
조성물 B 투여군 | 46.84 ± 0.77 | 44.66 ± 0.98 | 53.8 % 감소 |
조성물 C 투여군 | 46.70 ± 1.2 | 44.16 ± 1.72 | 56.9 % 감소 |
조성물 D 투여군 | 45.80 ± 0.82 | 43.73 ± 0.88 | 62.4 % 감소 |
메트포르민 250 mg/kg (양성 대조군) | 46.30 ± 1.3 | 44.20 ± 1.09 | 55.3 % 감소 |
시료명 | 혈중 아디포넥틴 함량변화 (㎍/㎖) | 정상군 대비 아디포넥틴 변화율(%) |
정상군 | 27.95 ± 2.86 | - |
음성 대조군 | 14.09 ± 2.80 | 49.58 % 감소 |
홍삼추출물 단독 투여군 | 16.92 ± 1.38 | 20.10 % 증가 |
조성물 A 투여군 | 19.42 ± 0.72 | 37.84 % 증가 |
조성물 B 투여군 | 19.59 ± 0.72 | 39.01 % 증가 |
조성물 C 투여군 | 20.01 ± 0.88 | 42.01 % 증가 |
조성물 D 투여군 | 21.20 ± 1.57 | 50.42 % 증가 |
메트포르민 250mg/kg (양성 대조군) | 20.05 ± 1.22 | 42.26 % 증가 |
시료명 | 혈중 렙틴 함량 (ng/㎖) | 정상군 대비 혈중 렙틴 변화율(%) |
정상군 | 2.81 ± 0.43 | - |
음성 대조군 | 22.53 ± 2.47 | 700.51 % 증가 |
홍삼추출물 단독 투여군 | 18.19 ± 1.16 | 19.28 % 감소 |
조성물 A 투여군 | 15.71 ± 2.94 | 30.25 % 감소 |
조성물 B 투여군 | 15.10 ± 1.33 | 32.97 % 감소 |
조성물 C 투여군 | 12.43 ± 0.62 | 44.83 % 감소 |
조성물 D 투여군 | 11.47 ± 1.33 | 49.08 % 감소 |
메트포르민 250mg/kg (양성 대조군) | 12.56 ± 1.39 | 44.26 % 감소 |
시료명 | 간 조직내 트리글리세리드 함량 (㎎/g liver) | 정상군 대비 트리글리세리드 함량 변화율 (%) |
정상군 | 30.97 ± 1.44 | - |
음성 대조군 | 49.81 ± 6.79 | 60.84 % 증가 |
홍삼추출물 단독 투여군 | 42.23 ± 4.52 | 15.23 % 감소 |
조성물A 투여군 | 37.59 ± 2.83 | 24.55 % 감소 |
조성물 B 투여군 | 36.84 ± 3.25 | 26.04 % 감소 |
조성물 C 투여군 | 35.61 ± 3.43 | 28.51 % 감소 |
조성물 D 투여군 | 34.70 ± 3.05 | 30.34 % 감소 |
메트포르민 250mg/kg (양성 대조군) | 65.40 ± 3.02 | 28.54 % 감소 |
Claims (5)
- 홍삼 추출물, 흑효모발효 추출물 및 길경 추출물을 유효성분으로 포함하는 비만 억제 또는 치료용 조성물.
- 제 1 항에서 있어서, 상기 유효성분은 조성물 전체 중량에 대하여 0.1 내지 30 중량%를 포함하는 것을 특징으로 하는 조성물.
- 제 1 항에서 있어서, 상기 조성물은 유효성분 전체 중량에 대하여 홍삼 추출물 0.01-70 중량%, 흑효모발효 추출물 0.01-50 중량% 및 길경 추출물 0.01-50 중량%를 포함하는 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 상기 조성물은 식품 조성물인 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 상기 조성물은 약제학적 조 성물인 것을 특징으로 하는 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080033538A KR101130740B1 (ko) | 2008-04-11 | 2008-04-11 | 비만 억제 또는 치료용 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080033538A KR101130740B1 (ko) | 2008-04-11 | 2008-04-11 | 비만 억제 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090108230A true KR20090108230A (ko) | 2009-10-15 |
KR101130740B1 KR101130740B1 (ko) | 2012-03-28 |
Family
ID=41551653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080033538A KR101130740B1 (ko) | 2008-04-11 | 2008-04-11 | 비만 억제 또는 치료용 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101130740B1 (ko) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101151690B1 (ko) * | 2010-08-30 | 2012-06-14 | 전북대학교산학협력단 | 비만 치료 대상을 선별하는 방법 및 조성물 |
JP2015081239A (ja) * | 2013-10-22 | 2015-04-27 | 株式会社アウレオ | 脂肪蓄積抑制剤 |
KR101685876B1 (ko) * | 2015-09-14 | 2016-12-13 | 경북대학교 산학협력단 | 길경추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 |
KR20190141349A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 글루칸 | 흑효모 발효 다당체를 유효성분으로 포함하는 장내 균총 개선 및 비만 예방, 치료용 조성물 |
JP2020533394A (ja) * | 2017-09-19 | 2020-11-19 | キュエゲン バイオテック カンパニー,リミテッド | 体脂肪減少補助剤およびベータグルカンを有効成分とする肥満の予防または治療用組成物 |
KR102346790B1 (ko) | 2021-04-29 | 2022-01-04 | 주식회사 에이스바이오메드 | 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020095513A (ko) * | 2001-06-14 | 2002-12-27 | 한국 한의학 연구원 | 비만억제용 길경 조성물 |
KR20030075441A (ko) * | 2002-03-19 | 2003-09-26 | 심인섭 | 비만억제 및 치료용 파낙사디올계 홍삼 사포닌 |
KR100873059B1 (ko) * | 2002-07-18 | 2008-12-09 | 주식회사 더멋진 바이오텍 | 베타글루칸의 지방축적 억제 용도 |
-
2008
- 2008-04-11 KR KR1020080033538A patent/KR101130740B1/ko active IP Right Grant
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101151690B1 (ko) * | 2010-08-30 | 2012-06-14 | 전북대학교산학협력단 | 비만 치료 대상을 선별하는 방법 및 조성물 |
JP2015081239A (ja) * | 2013-10-22 | 2015-04-27 | 株式会社アウレオ | 脂肪蓄積抑制剤 |
KR101685876B1 (ko) * | 2015-09-14 | 2016-12-13 | 경북대학교 산학협력단 | 길경추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 |
JP2020533394A (ja) * | 2017-09-19 | 2020-11-19 | キュエゲン バイオテック カンパニー,リミテッド | 体脂肪減少補助剤およびベータグルカンを有効成分とする肥満の予防または治療用組成物 |
KR20190141349A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 글루칸 | 흑효모 발효 다당체를 유효성분으로 포함하는 장내 균총 개선 및 비만 예방, 치료용 조성물 |
KR102346790B1 (ko) | 2021-04-29 | 2022-01-04 | 주식회사 에이스바이오메드 | 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제 |
EP4082537A1 (en) | 2021-04-29 | 2022-11-02 | Acebiomed, Inc. | Anti-obesity composition containing colchicine and metformin as effective agents |
Also Published As
Publication number | Publication date |
---|---|
KR101130740B1 (ko) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101130740B1 (ko) | 비만 억제 또는 치료용 조성물 | |
KR100877604B1 (ko) | 가공인삼 추출물을 함유하는 비만의 예방 및 치료용조성물 | |
WO2013040712A1 (en) | Composition comprising ku ding cha and ginseng for managing blood glucose levels | |
TWI694831B (zh) | 用於改善卵巢老化的包含人參果萃取物的組成物 | |
Tang et al. | Current progress in the hypoglycemic mechanisms of natural polysaccharides | |
KR101625474B1 (ko) | 진세노사이드 알에이치4의 대량 제조방법 | |
KR20150029852A (ko) | 꾸지뽕 추출물 또는 꾸지뽕 추출물 및 마카 추출물의 혼합물을 포함하는 성 호르몬 관련 질환 또는 증상의 예방, 치료 또는 개선용 조성물 | |
CN110604773B (zh) | 调节脂代谢紊乱的组合物及其制备方法和用途 | |
KR20120022134A (ko) | 한약재를 이용한 피로 회복 식품 | |
EP3025721B1 (en) | Pharmaceutical composition for preventing or treating asthma comprising pistacia weinmannifolia j. poiss. ex franch extract or fraction thereof | |
KR20200045982A (ko) | 도라지 사포닌을 포함하는 표준화된 도라지 추출물 또는 막분리 도라지 사포닌 추출물을 함유하는 간질환의 예방 또는 치료용 약학적 조성물 및 간기능 개선용 건강기능식품 | |
CN112618560B (zh) | 一种包含人参皂苷的药物组合物及其降血脂和抑制脂肪肝的用途 | |
KR102258590B1 (ko) | 다시마 및 한방 약재 추출물을 포함하는 호흡기 질환 개선용 조성물 | |
KR100815277B1 (ko) | 홍삼 산성다당체 및 구기자추출물을 함유하는 항고지혈증제 | |
KR101344189B1 (ko) | 발효 또는 미발효된 금은화 및 진피 혼합생약 추출물을 유효성분으로 함유하는 비만증의 예방 및 치료용 조성물 | |
KR20030080296A (ko) | 인삼으로부터 분리된 사포닌 분획 및 유도체를 함유하는알러지 질환의 예방 및 치료를 위한 조성물 | |
CN110652590B (zh) | 一种治疗糖尿病的中药复方及其制备方法和应用 | |
KR20140041024A (ko) | 알리움 후커리 추출물을 유효 성분으로 포함하는 비만 억제 또는 치료용 조성물 | |
KR20100062094A (ko) | 인삼열매, 인삼화 및 인삼줄기 추출물을 포함하는 알레르기예방 및 치료용 조성물 | |
CN113116955B (zh) | 一种含植物提取物的药物组合物及其应用 | |
CN1857395A (zh) | 治疗心脑血管疾病的中药复方组合物 | |
CN100355440C (zh) | 治疗ⅱ型糖尿病、降低血糖的中药复方制剂及其制备方法 | |
KR20100083598A (ko) | 인삼화 추출물을 유효성분으로 함유하는 제2형 당뇨병의 예방 및 치료용 조성물 | |
KR101662887B1 (ko) | 다래순 추출물을 유효성분으로 포함하는 비알콜성 지방간의 예방 또는 치료용 조성물 | |
KR20150111097A (ko) | 생지황, 구기자, 침향, 복령, 인삼 및 꿀 혼합물을 유효성분으로 함유하는 여성 불임 예방 및 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J121 | Written withdrawal of request for trial | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100818 Effective date: 20111125 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150223 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170303 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190305 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200204 Year of fee payment: 9 |